University of Texas , USA
Dr. Dima Suki completed her PhD from The University of Texas Houston Health Science Center.rnShe is Professor at The University of Texas MD Anderson Cancer Center in the Department ofrnNeurosurgery, as well as Director of Protocol Development and Data Management, and Co-Directorrnof Clinical Research. She also is adjunct Professor at Baylor College of Medicine, Department ofrnNeurosurgery. Dr. Suki serves on numerous committees, including the Institutional Review Board,rnwhere she is currently Associate Chair. Dr. Suki has over 100 peer-reviewed publications inrnscientific journals and has authored 7 book chapters and books. She serves on editorial advisoryrnboards for several scientific journals.
Glioblastoma multiforme (GBM) is a highly aggressive and rapidly fatal primary brainrntumor. Median patient survival is 12-14 months. Few treated patients survive beyond 5 years.rnVariation in characteristics such as age, performance status, and extent of resection (EOR) canrnextend survival for a few months. However, factors associated with long-term survivals of ≥5 yearsrnare largely unknown, and identifying them may provide insight into GBM and its management. Wernidentified consecutive patients surviving >5 years after initial GBM resection. Their prospectivelyrncollected demographics, clinical, imaging, and treatment data were retrospectively reviewed andrnanalyzed (under an IRB-approved protocol) from 6/1/1993 to 5/31/2010 (to allow for 5-yearsrnsurvival). EOR was measured volumetrically using pre- and post-op MRI’s. Among 701 newlyrndiagnosed GBM patients, 72 patients (10%) survived ≥5 years; the cohort’s overall median survivalrnwas 13.6 months. Four factors correlated significantly with longer survival on both univariate andrnmultivariate analyses: age, KPS, necrosis on the MRI, and EOR. These factors allowedrnclassification of patients into 4 groups whose >5 years survival varied widely. For patients withrn100% resections, >5-years survival is 50% for Group A, 21% for Group B, 13% for Group C, andrn2% for Group D. The corresponding numbers for patients with <100% resection are: 8% (Group A),rn13% (Group B), 1% (Group C), and 1% (Group D). This is the largest series of long-term GBMrnsurvivors (>5 years), emphasizing the importance of patient selection and of maximizing the EOR.